Pyxis Oncology Inc (PYXS) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control...

Form S-8 - Securities to be offered to employees in employee benefit plans

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at...

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024...

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company...